| "Reversible agranulocytosis with life-threatening sepsis occurred in a patient receiving levamisole immunotherapy for colonic carcinoma." | ( Cano, PO; Capek, A; Jerry, LM; Lewis, MG; Mansell, PW; Marquis, G; Parkinson, DR; Shibata, HR, 1977) |
| "Although the incidence of agranulocytosis did not seem to be reduced by any of the treatment schemes, high risk patients could be detected by the single day per week regimen." | ( Mielants, H; Veys, EM, 1978) |
| "Side effects included reversible agranulocytosis in 9 cases, on 3 occasions this necessitated the discontinuation of treatment." | ( Clot, J; Morlock, G; Sany, J; Serre, H, 1977) |
| "A 65-year-old woman developed agranulocytosis on two separate occasions following prophylactic administration of antibiotics before cardiac surgery." | ( Allo, M; Silva, J, 1977) |
| "A third type involves development of agranulocytosis following a latent period during which a sensitive patient is treated with large amounts of chlorpromazine." | ( Pisciotta, V, 1978) |
| "A case of agranulocytosis in a man with nonspecific seronegative polyarthritis treated with levamisole in the form of a proprietary veterinary anthelmintic is described." | ( du P Heyns, A; Retief, FP; Vorster, BJ, 1979) |
| "Two patients with agranulocytosis associated with diphenylhydantoin (DPH) therapy and clinical data suggesting suppression of granulopoiesis were investigated using in vitro culture techniques for committed granulocyte/macrophage precursors." | ( Lane, TA; Mendelsohn, J; Taetle, R, 1979) |
| "Patients with myelotoxic agranulocytosis were treated with gentamicin administered intravenously as drop-wise infusions in a dose of 5 mg/kg body weight a day every 8 hours." | ( Baranov, AE; Bodunkova, LE; Nadezhina, NM; Pozdniakova, VP; Shishkova, TV, 1979) |
| "On the fifth day of cimetidine therapy, agranulocytosis (800/ml) and a very low platelet count (40,000/ml) were observed; bone-marrow failure was documented both by biopsy and aspiration." | ( Druart, F; Frocrain, C; Martin, J; Matuchansky, C; Metois, P, 1979) |
| "In a 75-year-old man, agranulocytosis and septicemia developed after eight weeks of quinidine sulfate therapy." | ( Carr, RM; Eisner, EV; MacKinney, AR, 1977) |
| "She recovered from agranulocytosis after discontinuation of the drug and hospital treatment for 16 days." | ( Brown, BT; Jacknowitz, AI; Prince, RA, 1977) |
| "Thioridazine-hydrochloride-associated agranulocytosis usually occurs between the fifth and 11th week of therapy and is not related to the total dose of drug received." | ( Bogner, PJ; Ferguson, RL; Hodges, GR, 1977) |
| "The frequency of agranulocytosis in association with clozapine therapy has been estimated and compared with data reported for phenothiazine-induced agranulocytosis." | ( Anderman, B; Griffith, RW, 1977) |
| "Thirteen out of 17 deaths from agranulocytosis were attributed to co-trimoxazole treatment." | ( Inman, WH, 1977) |
| "An epidemic of agranulocytosis and granulocytopenia occurred in 1975 in conjunction with clozapine treatment of mental patients in Finland." | ( de la Chapelle, A; Hernberg, S; Kari, C; Nurminen, M, 1977) |
| "A case of agranulocytosis due to dapsone administered for the treatment of acne vulgaris is described." | ( Firkin, FC; Mariani, AF, 1977) |
| "The occurrence of a sudden outbreak of agranulocytosis in Finland among patients being treated with clozapine led to intensive investigations in an attempt to find a local precipitating factor." | ( Amsler, HA; Barth, E; Harjula, K; Teerenhovi, L; Vuopio, P, 1977) |
| "An allergic agranulocytosis developed after promethazine administration to a 34-year-old man with a compulsion neurosis." | ( Engel, H, 1976) |
| "A patient who was diagnosed as having agranulocytosis and thrombocytopenia after treatment with fluconazole was investigated and recovered after withdrawal of the antifungal therapy." | ( Katahira, H; Matsushima, T; Murakami, H; Sakura, T; Sawamura, M; Tamura, J; Tsuchiya, J, 1992) |
| "However, given the risk of agranulocytosis with clozapine, we suggest that the usual treatment strategies for akathisia be tried before clozapine is initiated in the approved manner." | ( Chengappa, KN; Ganguli, R; Kambhampati, RK; Levin, H; Mahdavi, N, 1992) |
| "The relative risk for agranulocytosis during sulphasalazine treatment was calculated to be 107 and 123 by the spontaneous reporting system and the case-control study, respectively." | ( Ekman, E; Keisu, M; Wiholm, BE, 1992) |
| "Granulocytopenia and agranulocytosis are severe side effects of clozapine therapy." | ( Barnas, C; Fleischhacker, WW; Hummer, M; Sperner-Unterweger, B; Stern, A; Zwierzina, H, 1992) |
| "The case of a patient in whom severe agranulocytosis developed after 7 weeks of clozapine treatment is presented." | ( Barnas, C; Fleischhacker, WW; Hummer, M; Sperner-Unterweger, B; Stern, A; Zwierzina, H, 1992) |
| "GM-CSF treatment for severe agranulocytosis deserves further investigation." | ( Jonson, B; Kanerud, L; Palmblad, J, 1990) |
| "Hypoplastic bone marrow associated with agranulocytosis is a well-known side effect of chlorpromazine treatment." | ( Ben-Yehuda, A; Bloom, A; Flusser, D; Lijovetzky, G; Tur-Kaspa, R, 1990) |
| "Two cases of agranulocytosis occurring after addition of a butyrophenone to a course of phenothiazine treatment are reported and possible mechanisms for this interaction are discussed." | ( Kehoe, R; Young, A, 1989) |
| "Four patients (Group I) developed agranulocytosis during a second course of MMI therapy and eight patients (Group II) during an initial course." | ( Komaki, G; Kuma, K; Kumagai, LF; Matsubayashi, S; Morita, T; Nagataki, S; Takaichi, Y; Tamai, H; Walter, RM, 1989) |
| "A 22-year-old female patient developed agranulocytosis 26 days after starting single agent treatment with perazine." | ( Ehninger, G; Gaertner, HJ; Hörner, W, 1985) |
| "Reversible agranulocytosis occurred following approximately 1 week of AZT therapy in a man with AIDS." | ( Goldsmith, JC; Irvine, W, 1989) |
| "Authors describe three cases of agranulocytosis in patients with giant cell (temporal) arterities treated with Dapsone and corticosteroids." | ( Bordessoule, D; Cransac, M; Fourgnaud-Gaillard, S; Liozon, E; Liozon, F; Rousset, H; Vidal, E; Weinbreck, P, 1988) |
| "Seven cases of agranulocytosis and two of liver damage that were probably due to amodiaquine treatment were studied." | ( Fehr, J; Frick, PG; Neftel, KA; Schmid, M; Woodtly, W, 1986) |
| "This paper reports a case of agranulocytosis that developed in a patient with hyperthyroidism two months after the administration of methimazole." | ( Hou, GL; Tsai, CC, 1988) |
| "Aplastic anaemia and agranulocytosis are uncommon but serious adverse effects of drug therapy." | ( Vincent, PC, 1986) |
| "A patient is presented who developed agranulocytosis while taking amodiaquine for suppressive therapy of malaria." | ( Gmür, J; Neftel, K; Schulthess, HK; von Felten, A, 1983) |
| "Because no cases of agranulocytosis were seen with methimazole doses less than 30 mg/d, low-dose methimazole therapy may be safer than high-dose therapy or treatment with conventional doses of propylthiouracil." | ( Cooper, DS; Daniels, GH; Goldminz, D; Ladenson, PW; Levin, AA; Molitch, ME; Ridgway, EC, 1983) |
| "A case of agranulocytosis in an 86-year-old man after 8 weeks treatment with quinidine sulfate is described." | ( Alexander, SJ; Gilmore, RI, 1984) |
| "3 A reversible agranulocytosis has been most commonly observed, occurring between four and six weeks of treatment." | ( Clink, HM, 1983) |
| "A 15-months-old boy developed agranulocytosis after administration of Chloramphenicol and Aminopyrine." | ( Alba, J; Fontán, G; García Rodriguez, MC; Lorente, F; Ojeda, JA, 1980) |
| "While neutropenia and agranulocytosis are not uncommon with chronic chlorpromazine therapy, neutropenia following an acute ingestion is unique but predictable in view of chlorpromazine's toxic effects on white cells." | ( Bruce, W; Burckart, GJ; Snidow, J, 1981) |
| "She developed complete agranulocytosis on peripheral smear within 3 weeks of the initiation of therapy." | ( Balkin, MS; Buchholtz, M; Green, AJ; Ortiz, J, 1993) |
| "Leukopenia and agranulocytosis in combination with a typical bone marrow, exhibiting a complete arrest of myelopoiesis at the stage of promyelocytes led to the diagnosis of an antithyroid therapy induced agranulocytosis." | ( Adorf, D; Grajer, KH; Kaboth, W; Nerl, C, 1994) |
| "Five patients with clozapine-induced agranulocytosis (granulocytes < 500/cu mm) were treated with the rG-CSF filgrastim, in addition to standard agranulocytosis therapy protocol." | ( Gullion, G; Yeh, HS, 1994) |
| "After onset of agranulocytosis, all patients were transferred to a medical service in a university hospital and treated with recombinant granulocyte colony-stimulating factor (filgrastim)." | ( Bellnier, TJ; Lamberti, JS; Schneider, E; Schwarzkopf, SB, 1995) |
| "A case of clozapine-induced agranulocytosis that was treated with a granulocyte colony-stimulating cytokine is presented." | ( Lippmann, SB; Mann, RM; Nguyen, VT; Ryabik, BM; Smith, JD, 1993) |
| "An 82-year-old woman developed agranulocytosis within two months of initiating sulfasalazine therapy." | ( Gales, BJ; Gales, MA, 1993) |
| "Clozapine may produce agranulocytosis in 1-2% of patients treated with it for 4 weeks or longer." | ( Cola, PA; Hasegawa, M; Meltzer, HY, 1994) |
| "The patients with agranulocytosis were treated with antibiotics and the patient with cholestasis received prednisone." | ( Frenkel, J; González, G; Michaud, P; Reyes, C; Téllez, R, 1993) |
| "A case report of clozapine-induced agranulocytosis in a patient treated concomitantly with lithium is reported." | ( Lahav, M; Modai, I; Valevski, A; Weizman, A, 1993) |
| "Episodes of agranulocytosis occurred in 61 patients within three months after they began treatment." | ( Alvir, JM; Lieberman, JA; Safferman, AZ; Schaaf, JA; Schwimmer, JL, 1993) |
| "The occurrence of agranulocytosis is a substantial hazard of the administration of clozapine, but this hazard can be reduced by monitoring the white-cell count." | ( Alvir, JM; Lieberman, JA; Safferman, AZ; Schaaf, JA; Schwimmer, JL, 1993) |
| "Two patients were treated for their agranulocytosis with granulocyte colony-stimulating factor (G-CSF; filgrastim)." | ( Haak, HL; Touw, DJ; van Melick, EJ, 1995) |
| "The average duration of agranulocytosis was not significantly different between the treated and untreated groups (6." | ( Baker, RW; Chengappa, KN; Gopalani, A; Haught, MK; McChesney, K; Schooler, NR, 1996) |
| "We have studied 6 patients with agranulocytosis treated with stimulating factors and 7 patients in historical control group." | ( Góra-Tybor, J; Krykowski, E; Robak, T, 1996) |
| "A thalassaemic girl presented with agranulocytosis, arthritis of both ankles and clinical and laboratory features consistent with the diagnosis of systemic vasculitis, during oral iron chelator L1 (deferiprone) treatment." | ( Castriota-Scanderbeg, A; Sacco, M, 1997) |
| "For treatment of clozapine-induced agranulocytosis, granulocyte colony-stimulating factors (G-CSF) are recommended." | ( Grond, M; Heiss, WD; Neveling, M; Rudolf, J, 1997) |
| "Reversible agranulocytosis and bone marrow suppression attributed to antibiotics developed in six patients after thiopental administration." | ( Stocker, R; Stover, JF, 1998) |
| "Thirty-nine patients reacted with agranulocytosis, while 75 patients had been treated for a minimum of 3 months without haematological side-effects." | ( Rane, A; Stjernberg, E; Wadelius, M; Wiholm, BE, 2000) |
| "Most of antithyroid drugs-induced agranulocytosis happens 2-12 weeks after the administration of antithyroid drug, and are related with the drug's doses." | ( Dai, W; Jin, H; Xu, B; Zhan, Z; Zhang, J, 1998) |
| "Clozapine medication may induce agranulocytosis in the treatment of a child with a schizophrenic psychosis." | ( Müller, H; Reitzle, K; Warnke, A; Wewetzer, C, 2001) |
| "In 17 of 18 patients, ATD-induced agranulocytosis developed within 2 to 12 weeks of starting ATD treatment." | ( Bai, Y; Dai, WX; Jin, H; Xin, WC; Xu, BZ; Yao, Y; Zhan, SW; Zhang, JD, 2002) |
| "Based on the sudden and late onset of agranulocytosis in our patient, clinicians may consider opting for weekly monitoring of hematologic function for patients on long-term clozapine therapy." | ( Bettinger, TL; Dorson, PG; Patel, NC, 2002) |
| "To calculate the risk of agranulocytosis associated to a drug is required to consider the basal risk of agranulocytosis in a general population as well as its possible modifications in the population of patients treated with the drug." | ( García, AG; Horga de la Parte, JF; Zapater Hernández, P, 2002) |
| "Estimated incidence rates of agranulocytosis in the IAAAS study and the calculated risk of dobesilate-associated agranulocytosis were used as background risks in a Poisson-based methodology, to calculate the number of coincidental reports of agranulocytosis among patients treated with dobesilate." | ( García, A; Horga, JF; Zapater, P, 2003) |
| "We experienced 4 cases of agranulocytosis due to anti-tuberculosis drugs (rifampicin [RFP], isoniazid [INH], ethambutol [EB], streptomycin [SM] or pyrazinamide [PZA]) among some 6,400 tuberculosis patients who underwent chemotherapy over the past 20 years from 1981 to 2002 in our hospital, and the incidence rate of agranulocytosis was estimated at 0." | ( Akagawa, S; Baba, M; Kawabe, Y; Komatsu, H; Kurashima, A; Machida, K; Masuda, K; Nagai, H; Nagayama, N; Shishido, Y; Tamura, A; Yotsumoto, H, 2003) |
| "We report on the first case of agranulocytosis with histological evidence of pure white cell aplasia associated with imipenem-cilastatin treatment." | ( Bourantas, K; Kalambokis, G; Tsianos, EV; Vassou, A, 2005) |
| "This study documents the incidences of agranulocytosis and neutropenia, and the patterns of incidence of the side effects of long-term clozapine treatment in order to determine an appropriate time to stop the Clozaril Patient Monitoring System (CPMS)." | ( Chae, BJ; Cho, MJ; Kang, BJ; Ko, J; Lee, Y; Oh, JT, 2006) |
| "To describe a case of agranulocytosis and severe hepatotoxicity associated with carbimazole treatment." | ( Aguilar-Diosdado, M; de Los Santos, A; Garcia-Valero, A; López-Tinoco, C; Torres, I; Vilchez, FJ, 2006) |
| "We examined the rates of leucopenia and agranulocytosis as reasons for discontinuation of clozapine in a sample of 1875 patients with schizophrenia treated in the State of Maryland." | ( Conley, RR; Dixon, L; Kelly, DL; Kreyenbuhl, J; Love, RC; Medoff, D, 2007) |
| "When neutropenia or agranulocytosis occur in people taking clozapine, cessation of treatment is mandated and relapse often results." | ( Taylor, D; Whiskey, E, 2007) |
| "We report on a patient who presented agranulocytosis and hemolytic anemia associated with this treatment regime." | ( Guedes Filho, G; Guedes, WR; Oliveira, BB; Oliveira, CA; Oliveira, DA; Silva, IM, 2009) |
| "As the risk of a second agranulocytosis is much higher in those patients, various methods of militating against repeat blood dyscrasias have been treated, including granulocyte colony-stimulating factor and lithium." | ( Herceg, M; Jukić, V; Muzinić, L, 2010) |
| "Dapsone-induced agranulocytosis is a rare but potentially fatal adverse effect of treatment for tuberculoid leprosy." | ( De Silva, GV; Jayawardana, MA; Murugathas, S; Riyaaz, AA; Satarasinghe, RL; Wickrmasingha, UD; Wijesinghe, R, 2009) |
| "Non chemotherapy drug-induced agranulocytosis is considered a potentially life-threatening idiosyncratic blood dyscrasia, thought to result from a partly elucidated immune and/or toxic damage on myelopoiesis, due to a multitude of drugs." | ( Papadaki, HA; Pontikoglou, C, 2010) |
| "Two patients experienced agranulocytosis that resolved without complications upon discontinuation of therapy." | ( El Alfy, M; El-Beshlawy, A; ElAlfy, MS; Lee, CL; Sari, TT; Tricta, F, 2010) |
| "In two patients this thiamazole-induced agranulocytosis/granulocytopenia only occurred after years of treatment." | ( Eland, IA; Jellema, WT; Stellingwerf, M; Wakelkamp, IM, 2011) |
| "The pathogenesis of agranulocytosis and pancytopenia might overlap, and additional studies are warranted to clarify this and to establish an optimal treatment strategy." | ( Ito, K; Kami, M; Kobayashi, K; Kunii, Y; Mukasa, K; Narimatsu, H; Noh, JY; Watanabe, N; Yamaguchi, T, 2012) |
| "This article presents two cases of agranulocytosis in patients treated with pegylated interferon and ribavirin due to chronic hepatitis C." | ( Dybowska, D; Halota, W; Karwowska, K; Kozielewicz, D, 2012) |
| "The case was complicated by an agranulocytosis after 3 weeks of antibiotic treatment induced by ceftriaxone." | ( Bertea, M; Braun, D; Günthard, HF; Horovitz, A; Jenni, R, 2010) |
| "This case report describes agranulocytosis immediately after oral administration of cibenzoline and dabigatran in a 70-year-old woman with paroxysmal atrial fibrillation (AF)." | ( Hayashi, H; Horie, M; Kitoh, K; Mitsunami, K, 2012) |
| "The neutropenia reduction to agranulocytosis was followed by successful methotrexate-corticosteroid therapy." | ( Balbir-Gurman, A; Hayek, T; Hoffman, R; Rozin, A, 2013) |
| "This is a rare case of agranulocytosis caused by rifampicin administered during anti-tuberculosis treatment in a chronic renal failure patient." | ( Sugiyama, M, 2012) |
| "Late-onset agranulocytosis is rare during treatment with clozapine, especially in monotherapy." | ( Cohen, D; Monden, M, 2013) |
| "Here, we report a patient who developed agranulocytosis, thrombocytopenia, and severe hepatic dysfunction on day 17 while receiving TZP treatment for an intracranial infection." | ( He, ZF; Wang, YP; Wu, XA, 2013) |
| "Although AMG does not cause agranulocytosis in most animals or humans, drugs associated with serious IDRs generally cause a higher incidence of mild reactions that resolve despite continued treatment." | ( Ng, W; Uetrecht, J, 2013) |
| "However, little is known with regard to agranulocytosis that develops after resumption of the same ATD treatment." | ( Ito, K; Iwaku, K; Kobayashi, S; Kunii, Y; Matsumoto, M; Mukasa, K; Noh, JY; Ohye, H; Sugino, K; Suzuki, M; Watanabe, N; Yoshihara, A, 2014) |
| "There were no cases in which agranulocytosis developed when treatment with the same ATD was resumed after discontinuation for less than five months." | ( Ito, K; Iwaku, K; Kobayashi, S; Kunii, Y; Matsumoto, M; Mukasa, K; Noh, JY; Ohye, H; Sugino, K; Suzuki, M; Watanabe, N; Yoshihara, A, 2014) |
| "In 4 patients, agranulocytosis occurred on MMI treatment, and in 3 patients on CBZ." | ( Cepková, J; Gabalec, F; Horáček, J; Svilias, I, 2014) |
| "We report four cases of agranulocytosis associated with ceftaroline use, highlighted by prolonged use (more than 14 days) and 8-hour dosing intervals or 12-hour dosing intervals with concomitant clindamycin therapy." | ( Chua, J; Lei, LR; Sakoulas, G; Varada, NL, 2015) |
| "In two thirds of the cases, agranulocytosis occurred within 6 weeks of permanent or intermittent metamizole treatment, in 30." | ( Bronder, E; Gundert-Remy, U; Ludwig, WD; Mühlbauer, B; Stammschulte, T, 2015) |
| "To examine the rate of neutropenia and agranulocytosis, and the pattern of development of these 2 disorders among Chinese patients prescribed clozapine treatment in a local psychiatric unit." | ( Lau, KL; Yim, PH, 2015) |
| "There were 114 cases of agranulocytosis attributable to ATD included, and their clinical characteristics and therapy outcomes were analyzed." | ( Dong, MJ; Liu, ZF; Weng, WW; Xu, Q; Yang, J; Zhang, J; Zhong, JJ; Zhu, YJ, 2016) |
| "For patients with ATD-induced agranulocytosis, G-CSF does not improve the recovery time of agranulocytosis, and (131)I is an optimal treatment approach." | ( Dong, MJ; Liu, ZF; Weng, WW; Xu, Q; Yang, J; Zhang, J; Zhong, JJ; Zhu, YJ, 2016) |
| "Clozapine-induced agranulocytosis (CIA)/clozapine-induced granulocytopenia (CIG) (CIAG) is a life-threatening event for schizophrenic subjects treated with clozapine." | ( Fujimoto, M; Fujita, K; Fukao, T; Hashimoto, N; Hashimoto, R; Hashimoto, S; Ikeda, M; Iwata, N; Kamatani, Y; Kanahara, N; Kawase, K; Kida, N; Kimura, T; Kondo, K; Kubo, M; Kubota, M; Makinodan, M; Murakami, M; Mushiroda, T; Nemoto, K; Nishihata, Y; Noda, T; Numata, S; Ohi, K; Ohmori, T; Otsuru, T; Ozeki, T; Saito, T; Shimasaki, A; Suwa, T; Takahashi, A; Takaki, M; Takeda, M; Ueno, S; Yada, Y; Yamamori, H; Yasuda, Y, 2016) |
| "Blood dyscrasias excluding agranulocytosis received limited attention in antipsychotic-treated patients during the first 18 weeks of therapy, although severe clinical conditions have been reported in a few cases." | ( Catapano, F; Fabrazzo, M; Maj, M; Monteleone, AM; Perris, F; Prisco, V; Sampogna, G, 2017) |
| "This case report describes agranulocytosis immediately after oral administration of dabigatran in a 68 years old man with atrial fibrillation (AF)." | ( Cosenza, G; Davì, S; Di Franco, F; Fasullo, S; Giubilato, A; La Manna, N; Maringhini, G; Vetrano, G, 2018) |
| "CONCLUSIONS Agranulocytosis induced by vancomycin is infrequent and generally occurs after day 12 of treatment." | ( Cabrera, MV; Castroagudin, A; di Fonzo, H; Mazzei, ME; Rueda, D; Villegas Gutsch, M, 2018) |
| "A 37-year-old Japanese female developed agranulocytosis and severe alopecia after initiation of AZA (50 mg), used as an alternative to mycophenolate mofetil (MMF, 1000 mg) therapy in anticipation of a planned pregnancy." | ( Andoh, A; Ishikura, K; Kamei, K; Kano, Y; Matsumura, S; Ogura, M; Saida, K; Sato, M, 2018) |
| "Prevalence estimates of agranulocytosis and related death in clozapine-treated patients were synthesized with the Comprehensive Meta-Analysis program using the random-effects model." | ( Li, XH; Lu, L; Ng, CH; Rao, WW; Ungvari, GS; Wang, G; Wang, S; Wang, SB; Xiang, YT; Zheng, W; Zhong, XM, 2020) |
| "We report a case of agranulocytosis resulting from ceftriaxone noted more than 3 weeks into therapy." | ( Arora, S; Genchanok, Y; Tolu, SS; Wang, H, 2019) |
| "Once this cause of agranulocytosis is identified, ceftriaxone therapy should be stopped; if the patient is febrile, an infectious disease workup should be performed and antibiotics should be started; and granulocyte colony-stimulating factor should be administered with daily monitoring of the absolute neutrophil count." | ( Arora, S; Genchanok, Y; Tolu, SS; Wang, H, 2019) |
| "The inherent risk of agranulocytosis associated with clozapine requires the realization of weekly white blood cell monitoring (WBCM) during the 18 first weeks of treatment." | ( Artarit, P; Chaslerie, A; Grall-Bronnec, M; Guerlais, M; Istvan, M; Jolliet, P; Laforgue, EJ; Vallot, G; Victorri-Vigneau, C, 2021) |
| "However, the high risk of agranulocytosis associated with clozapine therapy limits its clinical application." | ( Matsumoto, A; Noda, Y; Ozaki, N; Tashiro, Y; Torii-Goto, A; Ukigai, M; Yoshimi, A, 2022) |